复方阿嗪米特治疗重度糜烂性胃炎并发消化不良患者的效果及其对胃黏膜功能恢复的影响

Effect of compound azinomide in the treatment of severe erosive gastritis complicated with dyspepsia and influence on the recovery of gastric mucosa function

目的:研究复方阿嗪米特治疗重度糜烂性胃炎并发消化不良患者的效果及其对胃黏膜功能恢复的影响。方法:选取鹤壁市人民医院2021年9月至2023年5月收治的97例患者,随机分为常规组(n=48)和研究组(n=49)。常规组给予常规治疗,研究组联合复方阿嗪米特,两组患者均持续治疗4周,收集数据并比较两组患者疼痛程度、胃肠功能改善时间、胃肠激素水平、胃黏膜功能和不良反应。结果:研究组治疗后,腹痛腹胀消除时间、疼痛视觉模拟评分(VAS)、肠胃鸣恢复时间、肛门排气恢复时间别为(4.48±1.37)d、(2.08±0.68)分、(3.91±0.89)d、(4.32±1.10)d,均低于常规组(5.29±1.50)d、(2.95±0.74)分、(4.58±1.25)d、(5.02±1.35)d(P<0.01);研究组治疗后,胃蛋白酶原(PGⅡ、PGⅠ)、胃泌素-17(GAS-17)及5-羟色胺(5-HT)水平分别为(17.02±3.51)μg/L、(134.25±11.60)μg/L、(7.62±2.38)pmol/L、(191.20±12.58)mg/L,均高于常规组(13.92±3.25)μg/L、(120.58±9.84)μg/L、(5.84±2.12)pmol/L、(178.69±14.60)mg/L(P<0.001);研究组治疗后,碱性成纤维细胞生长因子(bFGF)、抗原Ki-67、表皮生长因子(EGF)水平分别为(492.66±35.26)×10^(3)、97.69±8.46、(349.84±22.65)×10^(3),均低于常规组的(520.12±38.62)×10^(3)、103.54±9.85、(368.25±25.98)×10^(3)(P<0.01)。结论:复方阿嗪米特能够有效减轻重度糜烂性胃炎并发消化不良患者的疼痛程度,调节胃肠激素水平,保护胃黏膜功能,促进胃肠功能恢复,安全性高。

Objective:To study the effect of compound azinomide in the treatment of severe erosive gastritis complicated with dyspepsia and its effect on the recovery of gastric mucosa function.Methods:Ninety-seven patients admitted to Hebi People’s Hospital from September 2021 to May 2023 were randomly divided into the conventional group(n=48)and the study group(n=49).The conventional group received conventional treatment,and the study group combined with compound azinomide.Both groups received continuous treatment for 4 weeks.Data were collected.The pain degree,gastrointestinal function improvement time,gastrointestinal hormone level,gastric mucosal function and adverse reactions were compared between the two groups.Results:After treatment,the time of abdominal pain and distension elimination,VAS score,gastrointestinal singing restoring time and anal exhaust restoring time in the study group were(4.48±1.37)d,(2.08±0.68)scores,(3.91±0.89)d and(4.32±1.10)d,respectively,which were lower than these in the conventional group(5.29±1.50)d,(2.95±0.74)scores,(4.58±1.25)d,(5.02±1.35)d(P<0.01).After treatment,the levels of pepsinogen(PGⅡ,PGⅠ),gastrin-17(GAS-17)and 5-hydroxytryptamine(5-HT)in the study group were(17.02±3.51)μg/L,(134.25±11.60)μg/L,(7.62±2.38)pmol/L and(191.20±12.58)mg/L,respectively,which were higher than these in the conventional group(13.92±3.25)μg/L,(120.58±9.84)μg/L,(5.84±2.12)pmol/L,(178.69±14.60)mg/L(P<0.001).After treatment,the levels of basic fibroblast growth factor(bFGF),antigen Ki-67 and epidermal growth factor(EGF)in the study group were(492.66±35.26)×10^(3),97.69±8.46 and(349.84±22.65)×10^(3),respectively,which were lower than(520.12±38.62)×10^(3),103.54±9.85,(368.25±25.98)×10^(3) in the conventional group(P<0.01).Conclusions:Compound azinomide treatment can effectively reduce the pain degree of patients with severe vesicant gastritis complicated with dyspepsia,regulate the level of gastrointestinal hormone,protect gastric mucosa function,promote the recovery of gastrointestinal function,and have high safety.